Rapid CommunicationsTreatment of erectile dysfunction with sildenafil☆
Section snippets
Patient screening and pretreatment evaluations
This was a prospective cohort study. The study included the first 100 men who elected to receive sildenafil therapy for the treatment of ED at a metropolitan Los Angeles urology practice, who met the study inclusion criteria, and who agreed to participate in a short-term, open-label, noncomparative trial (4 to 6 weeks in duration). Inclusion criteria were (1) a history of ED, as defined by the National Institutes of Health (NIH) Consensus Development Panel on Impotence,2 of at least 1 year in
Results
Of the first 100 patients electing to receive sildenafil, 74 completed the IIEF questionnaire both at baseline and at the follow-up visit. A summary of their baseline characteristics is shown in Table I. The mean ± SD age was 64 ± 11 years (range 29 to 80). The majority of patients (82%) had a history of concomitant medical conditions often associated with erectile dysfunction. Over the 4- to 6-week period, the mean number of tablets taken per patient was 4.5 ± 2.6. At the end of the study, 50
Comment
The advent of sildenafil has dramatically changed treatment of male ED. “Not surprisingly, patients are clamouring for the drug,”4 and, as noted earlier, physicians are responding positively to the demand. The safety and efficacy of sildenafil have been convincingly demonstrated in a large, rigorously controlled clinical trial.1 However, as with other treatments, major differences have been noted between results obtained in a clinical trial and those seen in a clinical practice setting. For
Conclusions
Sildenafil is an effective treatment of ED in a clinical practice setting. Previous data obtained from clinical trials are confirmed. The present findings, based largely on IIEF questionnaire responses, were substantiated by the responses of partners, who independently completed a modified version of the same questionnaire. Classifying the dysfunction according to severity appears to be a simple way to predict treatment response. Men who report some erectile function (severity class I or II)
References (7)
- et al.
The International Index of Erectile Function (IIEF)a multidimensional scale for assessment of erectile dysfunction
Urology
(1997) Sildenafilmedical advance or media event?
Lancet
(1998)- et al.
MUSE therapypreliminary clinical observations
Urology
(1997)
Cited by (111)
Development of an analytical method based on citric acid coated magnetite nanoparticles assisted dispersive magnetic solid-phase extraction for the enrichment and extraction of sildenafil, tadalafil, vardenafil and avanafil in human plasma and urine prior to determination by LC-MS/MS
2019, Microchemical JournalCitation Excerpt :After the development of PDE-5 inhibitor family drugs in 1998 [1], pharmacotherapy has gained wide acceptance as the first step treatment for erectile dysfunction (ED).
Postoperative Sexual Function
2011, Seminars in Colon and Rectal SurgeryT-Shaped Shunt and Intracavernous Tunneling for Prolonged Ischemic Priapism
2009, Journal of Urology
- ☆
Publication costs were supported in part by an unrestricted educational grant from Pfizer, Inc.